by Richard Daverman, PhD
December 20, 2013 -- Chengdu Kanghong Pharmaceutical Group was granted CFDA approval for Compaq Sipp ophthalmic injection (conbercept), a novel treatment for wet age-related macular degeneration. The drug is the first innovative, China-developed monoclonal antibody to gain regulatory approval, a significant milestone. The company believes its drug offers significant advantages over existing western MAbs such as Roche/Genentech’s similar drug, which is marketed as Avastin and Lucentis, giving conbercept the potential to become a blockbuster. More details....
Help employers find you! Check out all the jobs and post your resume.
